Fernandez-Pol Sebastian, Ma Lisa, Joshi Rohan P, Arber Daniel A
Department of Pathology, Stanford University, Stanford, CA.
Department of Pathology, University of Chicago, Chicago, IL.
Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):416-422. doi: 10.1097/PAI.0000000000000644.
Here, we utilize a high throughput sequencing panel that covers several genes known to be recurrently mutated in certain T-cell lymphoma subtypes as well as genes frequently mutated in other hematolymphoid malignancies, including myeloid neoplasms. This panel was applied to formalin-fixed, paraffin-embedded tissue from 84 biopsies from 78 patients selected for this study. The biopsies included ones a with a diagnosis of T-cell lymphoma (n=79), including peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; n=26) and angioimmunoblastic T-cell lymphoma (AITL; n=13), as well as 5 cases of atypical T-cell proliferations. KMT2C and KMT2D, which code for proteins involved in histone modifications, were the 2 most frequently mutated genes in our cohort and were altered across a range T-cell lymphomas. Mutations in TET2 and DNMT3A, which are involved in regulating DNA methylation, were also found in a variety of T-cell lymphoma categories. The RHOA G17V mutation that is frequently found in AITL was identified 5 of 13 (40%) cases of AITL and in 3 of 26 (12%) cases of PTCL-NOS, but not in biopsies involved by other T-cell proliferations. Our study adds to the already significant evidence from other investigators that, among T-cell lymphomas, the RHOA G17V variant is specific for AITL and PTCL-NOS. In contrast, variants in epigenetic modifier genes do not appear to be particularly specific for T-cell lymphoma subcategories evaluated in our study.
在此,我们使用了一个高通量测序面板,该面板涵盖了已知在某些T细胞淋巴瘤亚型中经常发生突变的几个基因,以及在其他血液淋巴系统恶性肿瘤(包括髓系肿瘤)中经常发生突变的基因。该面板应用于来自78名入选本研究患者的84份活检标本的福尔马林固定、石蜡包埋组织。活检标本包括诊断为T细胞淋巴瘤的标本(n = 79),包括未另行指定的外周T细胞淋巴瘤(PTCL-NOS;n = 26)和血管免疫母细胞性T细胞淋巴瘤(AITL;n = 13),以及5例非典型T细胞增殖病例。编码参与组蛋白修饰的蛋白质的KMT2C和KMT2D是我们队列中最常发生突变的两个基因,并且在一系列T细胞淋巴瘤中均发生改变。参与调节DNA甲基化的TET2和DNMT3A的突变也在多种T细胞淋巴瘤类别中被发现。在13例AITL病例中有5例(40%)以及在26例PTCL-NOS病例中有3例(12%)中鉴定出了AITL中常见的RHOA G17V突变,但在其他T细胞增殖相关的活检标本中未发现。我们的研究进一步补充了其他研究者已有的重要证据,即在T细胞淋巴瘤中,RHOA G17V变体对AITL和PTCL-NOS具有特异性。相比之下,表观遗传修饰基因的变体似乎对我们研究中评估的T细胞淋巴瘤亚类没有特别的特异性。